8-K Announcements
6Material company update
Mar 27, 2026·SEC
Material company update
Mar 10, 2026·SEC
Material company update
Feb 26, 2026·SEC
Rocket Pharmaceuticals, Inc.(RCKT)Earnings, Financials & Key Ratios
RCKT•NASDAQ
$3.86
$418M mkt cap·Price updated May 6, 2026
AboutRocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; CIEMAT and UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. is headquartered in Cranbury, New Jersey.Show more
- Revenue$0
- EBITDA-$232M+12.2%
- Net Income-$223M+13.8%
- EPS (Diluted)-2.01+26.4%
- ROE-60.27%-11.3%
- ROIC-63.25%-21.4%
- Debt/Equity0.09+63.0%
RCKT Key Insights
Rocket Pharmaceuticals, Inc. (RCKT) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
✗Weaknesses
- ✗Weak Piotroski F-Score: 1/9
- ✗Shares diluted 17.2% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
RCKT Price & Volume
Rocket Pharmaceuticals, Inc. (RCKT) stock price & volume — 10-year historical chart
Loading chart...
RCKT Growth Metrics
Rocket Pharmaceuticals, Inc. (RCKT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM13.77%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM26.37%
Return on Capital
10 Years-40.02%
5 Years-48.29%
3 Years-54.55%
Last Year-58.87%
RCKT Recent Earnings
Rocket Pharmaceuticals, Inc. (RCKT) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (75%)
Q1 2026Latest
Feb 26, 2026EPS
$0.38
Est $0.42
+9.5%
Revenue
—
Est $277,778
Q4 2025
Nov 6, 2025EPS
$0.45
Est $0.48
+6.3%
Revenue
—
Est $312,500
Q3 2025
Aug 7, 2025EPS
$0.59
Est $0.57
-3.5%
Revenue
—
Est $4M
Q2 2025
May 8, 2025EPS
$0.56
Est $0.59
+5.1%
Revenue
—
Est $800,000
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q1 2026Latest | Feb 26, 2026 | $0.38vs $0.42+9.5% | —vs $277,778 |
| Q4 2025 | Nov 6, 2025 | $0.45vs $0.48+6.3% | —vs $312,500 |
| Q3 2025 | Aug 7, 2025 | $0.59vs $0.57-3.5% | —vs $4M |
| Q2 2025 | May 8, 2025 | $0.56vs $0.59+5.1% | —vs $800,000 |
Based on last 12 quarters of dataView full earnings history →
RCKT Peer Comparison
Rocket Pharmaceuticals, Inc. (RCKT) competitors in Cell and Gene Therapy Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 CRSP | 4.92B | 52.38 | -8.10 | -89.97% | -13.29% | -25.49% | 0.11 | |
 EDIT | 297.52M | 3.04 | -1.69 | -100% | -5.23% | 0.66 | ||
 BEAM | 2.97B | 28.90 | -35.68 | 120.01% | -57.24% | -7.31% | 0.24 | |
 NTLA | 1.55B | 13.31 | -3.49 | -100% | -61.47% | 0.14 | ||
 SGMO | 37.8M | 0.18 | -0.36 | -67.2% | -331.28% | -8.14% | 1.34 | |
 RARE | 2.46B | 25.01 | -4.29 | 20.13% | -85.54% | -9.11% | ||
 FOLD | 4.47B | 14.49 | -80.50 | 32.29% | -2.35% | -6.1% | 2.29 | |
 ACAD | 3.78B | 22.35 | 16.43 | 31.85% | 24.94% | 28.47% | 4.16% | 0.07 |
Compare RCKT vs Peers
Rocket Pharmaceuticals, Inc. (RCKT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
RCKT Income Statement
Rocket Pharmaceuticals, Inc. (RCKT) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 204K | 330K | 426K | 1.15M | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - |
| Gross Profit | -204K▲ 0% | -330K▼ 61.8% | -426K▼ 29.1% | -1.15M▼ 168.8% | 0▲ 100.0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% |
| Gross Margin % | - | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | -20.71% | -61.76% | -29.09% | -168.78% | 100% | - | - | - | - |
| Operating Expenses | 26.74M | 70.97M | 75.9M | 134.86M | 167.25M | 224.34M | 259.66M | 273.2M | 231.75M |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 12.54M | 17.89M | 17.53M | 27.92M | 41.77M | 58.77M | 73.32M | 101.96M | 86.5M |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | - |
| Research & Development | 14.19M | 53.27M | 58.62M | 106.38M | 125.48M | 165.57M | 186.34M | 171.24M | 142.01M |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | -186K | -250K | 0 | 0 | 0 | 0 | 0 | 3.23M |
| Operating Income | -26.74M▲ 0% | -71.16M▼ 166.1% | -76.15M▼ 7.0% | -136M▼ 78.6% | -167.25M▼ 23.0% | -224.34M▼ 34.1% | -259.66M▼ 15.7% | -273.2M▼ 5.2% | -231.75M▲ 15.2% |
| Operating Margin % | - | - | - | - | - | - | - | - | - |
| Operating Income Growth % | 36.16% | -166.13% | -7.02% | -78.6% | -22.97% | -34.14% | -15.74% | -5.22% | 15.17% |
| EBITDA | -26.53M | -70.83M | -75.72M | -134.86M | -161.88M | -218.08M | -252.56M | -263.83M | -231.75M |
| EBITDA Margin % | - | - | - | - | - | - | - | - | - |
| EBITDA Growth % | 36.39% | -166.94% | -6.92% | -78.09% | -20.03% | -34.72% | -15.81% | -4.46% | 12.16% |
| D&A (Non-Cash Add-back) | 204K | 330K | 426K | 1.15M | 5.37M | 6.27M | 7.1M | 9.38M | 0 |
| EBIT | -20.21M | -68.67M | -71.56M | -132.73M | -163.18M | -219.95M | -243.72M | -256.86M | 0 |
| Net Interest Income | -2.76M | -3.55M | -1.37M | -5.4M | -2.82M | 1.98M | 14.06M | 16.34M | 0 |
| Interest Income | 819K | 1.69M | 3.41M | 2.15M | 3.07M | 3.89M | 15.94M | 18.22M | 0 |
| Interest Expense | 3.58M | 5.24M | 4.78M | 7.55M | 5.89M | 1.91M | 1.88M | 1.89M | -1.89M |
| Other Income/Expense | -2.76M | -3.36M | -1.12M | -3.7M | -1.82M | 2.48M | 14.06M | 14.46M | 8.62M |
| Pretax Income | -29.5M▲ 0% | -74.52M▼ 152.6% | -77.27M▼ 3.7% | -139.7M▼ 80.8% | -169.07M▼ 21.0% | -221.86M▼ 31.2% | -245.59M▼ 10.7% | -258.75M▼ 5.4% | -223.12M▲ 13.8% |
| Pretax Margin % | - | - | - | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 6.97M | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | -4.99% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -29.5M▲ 0% | -74.52M▼ 152.6% | -83.23M▼ 11.7% | -146.67M▼ 76.2% | -169.07M▼ 15.3% | -221.86M▼ 31.2% | -245.59M▼ 10.7% | -258.75M▼ 5.4% | -223.12M▲ 13.8% |
| Net Margin % | - | - | - | - | - | - | - | - | - |
| Net Income Growth % | 31.17% | -152.63% | -11.69% | -76.22% | -15.27% | -31.23% | -10.7% | -5.35% | 13.77% |
| Net Income (Continuing) | -29.5M | -74.52M | -77.27M | -146.67M | -169.07M | -221.86M | -245.59M | -258.75M | -223.12M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -4.36▲ 0% | -1.89▲ 56.7% | -1.70▲ 10.1% | -2.52▼ 48.2% | -2.68▼ 6.3% | -3.26▼ 21.6% | -2.92▲ 10.4% | -2.73▲ 6.5% | -2.01▲ 26.4% |
| EPS Growth % | 31.98% | 56.65% | 10.05% | -48.24% | -6.35% | -21.64% | 10.43% | 6.51% | 26.37% |
| EPS (Basic) | -4.36 | -1.89 | -1.70 | -2.52 | -2.68 | -3.26 | -2.92 | -2.73 | -2.01 |
| Diluted Shares Outstanding | 6.77M | 39.38M | 49.01M | 55.38M | 63.24M | 68.15M | 84.01M | 94.81M | 111.12M |
| Basic Shares Outstanding | 6.77M | 39.38M | 49.01M | 55.38M | 63.24M | 68.15M | 84.01M | 94.81M | 111.12M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
RCKT Balance Sheet
Rocket Pharmaceuticals, Inc. (RCKT) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 101.05M | 209.09M | 307.75M | 487.35M | 392.06M | 364.06M | 378.22M | 378.18M | 192.73M |
| Cash & Short-Term Investments | 100.01M | 205.73M | 304.12M | 482.72M | 388.74M | 356.39M | 373.18M | 372.34M | 77.56M |
| Cash Only | 78.72M | 111.36M | 185.38M | 297.1M | 232.69M | 140.52M | 55.9M | 163.63M | 77.56M |
| Short-Term Investments | 21.29M | 94.38M | 118.73M | 185.62M | 156.05M | 215.88M | 317.27M | 208.7M | 0 |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 3.36M | 0 | 0 | 0 | 7.67M | 5.05M | 5.85M | 115.18M |
| Total Non-Current Assets | 731K | 42.23M | 64.37M | 103.48M | 104.96M | 187.75M | 188.12M | 149.52M | 137.72M |
| Property, Plant & Equipment | 563K | 2.03M | 31.35M | 70.64M | 72.35M | 77.64M | 87.59M | 83.32M | 71.59M |
| Fixed Asset Turnover | - | - | - | - | - | - | - | - | - |
| Goodwill | 0 | 30.82M | 30.82M | 30.82M | 30.82M | 39.15M | 39.15M | 39.15M | 39.15M |
| Intangible Assets | 0 | 0 | 226K | 0 | 0 | 25.72M | 25.15M | 25.15M | 25.15M |
| Long-Term Investments | 207K | 7.4M | 1.52M | 0 | 0 | 43.28M | 34.32M | 0 | 0 |
| Other Non-Current Assets | -39K | 1.44M | 1.98M | 3.59M | 1.8M | 1.95M | 1.91M | 1.89M | 1.82M |
| Total Assets | 101.78M▲ 0% | 251.31M▲ 146.9% | 372.12M▲ 48.1% | 590.82M▲ 58.8% | 497.02M▼ 15.9% | 551.81M▲ 11.0% | 566.34M▲ 2.6% | 527.7M▼ 6.8% | 330.45M▼ 37.4% |
| Asset Turnover | - | - | - | - | - | - | - | - | - |
| Asset Growth % | -21.5% | 146.92% | 48.07% | 58.77% | -15.88% | 11.02% | 2.63% | -6.82% | -37.38% |
| Total Current Liabilities | 4.07M | 15.37M | 18.31M | 32.62M | 22.17M | 39.17M | 48.51M | 40.68M | 30.21M |
| Accounts Payable | 451K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Payables Outstanding | 806.94 | - | - | - | - | - | - | - | - |
| Short-Term Debt | 0 | 0 | 957K | 4.88M | 0 | 0 | 0 | 0 | 2.92M |
| Deferred Revenue (Current) | 506K | 534K | 562K | 590K | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 557K | 12.93M | 12.68M | 2M | 4.53M | 10.01M | 9.93M | 11.94M | 27.29M |
| Current Ratio | 24.83x | 13.60x | 16.81x | 14.94x | 17.69x | 9.29x | 7.80x | 9.30x | 6.38x |
| Quick Ratio | 24.83x | 13.60x | 16.81x | 14.94x | 17.69x | 9.29x | 7.80x | 9.30x | 6.38x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 49.94M | 41.9M | 46.52M | 54.69M | 20.13M | 22.95M | 25.26M | 23.78M | 23.02M |
| Long-Term Debt | 49.54M | 41.45M | 45.05M | 35.07M | 0 | 0 | 0 | 0 | 21.96M |
| Capital Lease Obligations | 0 | 0 | 1.44M | 19.49M | 20.05M | 20.36M | 22.33M | 22.64M | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 403K | 457K | 23K | 136K | 80K | 2.6M | 2.94M | 1.14M | 1.06M |
| Total Liabilities | 54.01M | 57.28M | 64.82M | 87.31M | 42.3M | 62.12M | 73.77M | 64.47M | 53.23M |
| Total Debt | 49.54M | 41.45M | 47.45M | 61.7M | 22.6M | 22.87M | 25.04M | 25.5M | 24.88M |
| Net Debt | -29.18M | -69.91M | -137.93M | -235.4M | -210.09M | -117.65M | -30.86M | -138.14M | -52.68M |
| Debt / Equity | 1.04x | 0.21x | 0.15x | 0.12x | 0.05x | 0.05x | 0.05x | 0.06x | 0.09x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Interest Coverage | -7.47x | -13.58x | -15.92x | -18.02x | -28.40x | -117.52x | -138.48x | -144.86x | - |
| Total Equity | 47.76M▲ 0% | 194.04M▲ 306.2% | 307.3M▲ 58.4% | 503.52M▲ 63.9% | 454.72M▼ 9.7% | 489.69M▲ 7.7% | 492.57M▲ 0.6% | 463.23M▼ 6.0% | 277.22M▼ 40.2% |
| Equity Growth % | -34.72% | 306.24% | 58.37% | 63.85% | -9.69% | 7.69% | 0.59% | -5.96% | -40.16% |
| Book Value per Share | 7.06 | 4.93 | 6.27 | 9.09 | 7.19 | 7.19 | 5.86 | 4.89 | 2.49 |
| Total Shareholders' Equity | 47.76M | 194.04M | 307.3M | 503.52M | 454.72M | 489.69M | 492.57M | 463.23M | 277.22M |
| Common Stock | 68K | 452K | 548K | 610K | 645K | 791K | 903K | 1.06M | 1.08M |
| Retained Earnings | -268.37M | -105.87M | -183.14M | -322.84M | -491.91M | -713.77M | -959.37M | -1.22B | -1.44B |
| Treasury Stock | 263.94M | -668K | -53K | 0 | 0 | -47K | 0 | 0 | 0 |
| Accumulated OCI | -16K | -127K | 20K | -42K | -161K | -357K | 319K | 66K | -31K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
RCKT Cash Flow Statement
Rocket Pharmaceuticals, Inc. (RCKT) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -26.11M | -53.79M | -64.66M | -74.64M | -121.16M | -178.14M | -194.92M | -209.72M | -190.01M |
| Operating CF Margin % | - | - | - | - | - | - | - | - | - |
| Operating CF Growth % | 29.93% | -105.99% | -20.22% | -15.43% | -62.33% | -47.03% | -9.42% | -7.6% | 9.4% |
| Net Income | -29.5M | -74.52M | -77.27M | -139.7M | -169.07M | -221.86M | -245.59M | -258.75M | -223.12M |
| Depreciation & Amortization | 200K | 330K | 426K | 1.15M | 5.37M | 6.27M | 7.1M | 9.38M | 11.03M |
| Stock-Based Compensation | 4.04M | 13.6M | 13.37M | 18.57M | 29.24M | 31.01M | 39.41M | 43.92M | 37.06M |
| Deferred Taxes | 654K | -484K | -1.07M | 999K | 3.15M | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 522K | 2.9M | 3.6M | 29.32M | 13.53M | 370K | -9.28M | -6.19M | -14.97M |
| Working Capital Changes | -2.03M | 4.38M | -3.73M | 15.03M | -3.39M | 6.08M | 13.46M | 1.92M | 0 |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | -1.14M | 5.89M | -2.72M | 11.02M | -4.83M | 9.67M | 0 | 0 | -10.35M |
| Cash from Investing | 75.02M | -5.27M | -39.01M | -96.59M | 18.85M | -69.33M | -98.07M | 131.71M | 103.77M |
| Capital Expenditures | -70K | -1.45M | -23.27M | -29.06M | -7.71M | -8.62M | -16.47M | -5.86M | -440K |
| CapEx % of Revenue | - | - | - | - | - | - | - | - | - |
| Acquisitions | 0 | 76.35M | 15.74K | 8.45M | 95K | 42.73M | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | -356K | -15.74K | -8.45M | -95K | 0 | 0 | 0 | 0 |
| Cash from Financing | 25.41K | 153.5M | 177.79M | 282.99M | 37.68M | 155.29M | 208.4M | 185.74M | 148K |
| Debt Issued (Net) | 0 | 0 | 0 | 5.56M | 201K | 172K | 139K | 0 | 0 |
| Equity Issued (Net) | 0 | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | -668K | 0 | -72K | 0 | -47K | 0 | 0 | 0 |
| Other Financing | 19K | 148K | -313K | -3.85M | -201K | -172K | -132K | 0 | 148K |
| Net Change in Cash | 48.92M▲ 0% | 94.44M▲ 93.0% | 74.12M▼ 21.5% | 111.76M▲ 50.8% | -64.63M▼ 157.8% | -92.18M▼ 42.6% | -84.58M▲ 8.2% | 107.72M▲ 227.4% | -86.1M▼ 179.9% |
| Free Cash Flow | -26.18M▲ 0% | -55.24M▼ 111.0% | -87.93M▼ 59.2% | -103.7M▼ 17.9% | -128.88M▼ 24.3% | -186.76M▼ 44.9% | -211.39M▼ 13.2% | -215.59M▼ 2.0% | -190.45M▲ 11.7% |
| FCF Margin % | - | - | - | - | - | - | - | - | - |
| FCF Growth % | 30.65% | -110.99% | -59.18% | -17.93% | -24.28% | -44.91% | -13.19% | -1.99% | 11.66% |
| FCF per Share | -3.87 | -1.40 | -1.79 | -1.87 | -2.04 | -2.74 | -2.52 | -2.27 | -1.71 |
| FCF Conversion (FCF/Net Income) | 0.89x | 0.72x | 0.78x | 0.51x | 0.72x | 0.80x | 0.79x | 0.81x | 0.85x |
| Interest Paid | 0 | 4.49M | 2.99M | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 2K | 26K | 0 | 0 | 0 | 0 | 0 | 0 |
RCKT Key Ratios
Rocket Pharmaceuticals, Inc. (RCKT) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -47.1% | -48.78% | -61.64% | -33.2% | -36.18% | -35.29% | -46.98% | -50.01% | -54.14% | -60.27% |
| Return on Invested Capital (ROIC) | -51.87% | -36.16% | -74.79% | -38.92% | -46.63% | -48.93% | -54.57% | -46.72% | -52.08% | -63.25% |
| Debt / Equity | 0.67x | 1.04x | 0.21x | 0.15x | 0.12x | 0.05x | 0.05x | 0.05x | 0.06x | 0.09x |
| Interest Coverage | -29.53x | -7.47x | -13.58x | -15.92x | -18.02x | -28.40x | -117.52x | -138.48x | -144.86x | - |
| FCF Conversion | 0.87x | 0.89x | 0.72x | 0.78x | 0.51x | 0.72x | 0.80x | 0.79x | 0.81x | 0.85x |
RCKT SEC Filings & Documents
Rocket Pharmaceuticals, Inc. (RCKT) SEC filings — annual & quarterly reports (10-K, 10-Q)
RCKT Frequently Asked Questions
Rocket Pharmaceuticals, Inc. (RCKT) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Rocket Pharmaceuticals, Inc. (RCKT) grew revenue by 0.0% over the past year. Growth has been modest.
Rocket Pharmaceuticals, Inc. (RCKT) reported a net loss of $223.1M for fiscal year 2025.
Dividend & Returns
Rocket Pharmaceuticals, Inc. (RCKT) has a return on equity (ROE) of -60.3%. Negative ROE indicates the company is unprofitable.
Rocket Pharmaceuticals, Inc. (RCKT) had negative free cash flow of $190.5M in fiscal year 2025, likely due to heavy capital investments.
Explore More RCKT
Rocket Pharmaceuticals, Inc. (RCKT) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates